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Abstract 
Background 
European regional variation in cancer survival was reported in the EUROCARE-4 study 
for patients diagnosed in 1995-1999. Relative survival (RS) estimates are here updated 
for patients diagnosed with cancer of the oesophagus, stomach, and small intestine from 
2000 to 2007. Trends in RS from 1999-2001 to 2005-2007 are presented to monitor and 
discuss improvements in patient survival in Europe.  
 
Materials and Methods 
EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1- 
and 5-year RS. Using registry-specific life-tables stratified by age, gender, and calendar 
year, age-standardised ‘complete analysis’ RS estimates by country and region were 
calculated for Northern, Southern, Eastern and Central Europe, and for Ireland and United 
Kingdom (UK). Survival trends of patients in periods 1999-2001, 2002-2004, and 2005-
2007 were investigated using the ‘period’ RS approach. We computed the 5-year RS 
conditional on surviving the first year (5-year conditional survival), as the ratio of age-
standardised 5-year RS to 1-year RS. 
 
Results 
Oesophageal cancer 1- and 5-year RS (40% and 12%, respectively) remained poor in 
Europe. Patient survival was worst in Eastern (8%), Northern (11%), and Southern 
Europe (10%). Europe-wide, there was a 3% improvement in oesophageal cancer 5-year 
survival by 2005-2007, with Ireland and the UK (3%), and Central Europe (4%) showing 
large improvements. 
Europe-wide, stomach cancer 5-year RS was 25%. Ireland and UK (17%) and Eastern 
Europe (19%) had the poorest 5-year patient survival. Southern Europe had the best 5-
year survival (30%), though only showing an improvement of 2% by 2005-2007.  
Small intestine cancer 5-year RS for Europe was 48%, with Central Europe having the 
best (54%), and Ireland and UK the poorest (37%). Five-year patient survival 
improvement for Europe was 8% by 2005-2007, with Central, Southern, and Eastern 
Europe showing the greatest increases (≥9%). 
 
Conclusions 
Survival for these cancer sites, particularly oesophageal cancer, remains poor in Europe 
with wide variation. Further investigation into the wide variation, including analysis by 
histology and anatomical sub-site, will yield insight to better monitor and explain the 
improvements in survival observed over time.
Introduction 
This article focuses on European relative survival (RS) estimates and trends for 
oesophageal, stomach and small intestine cancer patients, diagnosed up to 2007, with 
follow-up to December 31
st
 2008, as part of EUROCARE-5. Regional variation in RS 
estimates throughout Europe has been consistently reported for cancer patients, including 
upper gastrointestinal tract cancers, diagnosed in 1990-1994 [1], 1995-1999 [2] and 1999-
2007 [3]. 
 
Oesophageal cancer ranks as the eighth most common cancer worldwide with 
approximately 5 cases per 100,000 diagnosed in Europe annually [4]. Two main 
histological subtypes, adenocarcinoma (OAC) and squamous cell carcinoma (OSCC), 
display regional variation in incidence across Europe [5]. Stomach cancer is the third 
most common cause of cancer death globally [6]. Wide variation in stomach cancer 
incidence across Europe has been reported with recent declines in most European 
countries as a result of lifestyle changes, Helicobacter pylori detection and cancer 
treatment. Incidence of non-cardia tumors is high in Southern Europe [7] which, 
correspondingly, has the best 5-year patient survival [3]. While the small intestine 
comprises 90% of the length of the bowel, small intestine cancers are rare with an age-
standardised incidence rate of 2 per 100,000 person-years in the USA [8] with lower 
incidence rates reported within Europe [9]. Small intestine cancers exhibit a diverse 
histology with adenocarcinomas, carcinoid (now classified as neuroendocrine), 
lymphomas and sarcomas most common [10]. Incidence of small intestine cancers, 
particularly neuroendocrine malignancies, have increased in the USA [11,12] and Sweden 
[13], likely as a result of improved detection and classification. Neuroendocrine small 
intestine cancers are the most common histological subtype and confer superior prognosis 
compared to other small intestine entities [12]. Incidence of epithelial small intestine 
cancers is reportedly highest in Northern and lowest in Eastern Europe [14]; possibly due 
to geographic differences in diagnostic testing and variable capture by cancer registries.  
 
Methods 
Methods used for the analysis of EUROCARE-5 data are described in a dedicated paper 
in this EJC issue [15]. Briefly, survival data were obtained from 29 countries, 21 with 
100% national coverage, from 87 cancer registries. Countries were grouped into 
Northern, Central, Southern and Eastern Europe and Ireland and UK. 
 
All patients diagnosed with a primary and malignant oesophageal, stomach or small 
intestine cancer, as identified by topography codes C15, C16 (cardia C16.0 and non-
cardia C16.1-C16.6) and C17, respectively, of the International Classification of Diseases 
for Oncology, 3
rd
 edition (ICD-O-3), diagnosed from 2000-2007 were included. Patients 
with morphology codes 9590-9989 (ICD-O-3), or who were diagnosed by death 
certificate only (DCO), autopsy only, or censored with null survival time, were excluded. 
Patients were not excluded if they had a previous primary tumour. All the registries with 
less than 13% of DCO (for all cancers combined) were included in the analysis. 
 
One-year RS, 5-year RS and 5-year RS conditional on surviving the first year after 
diagnosis (5-year conditional) were estimated using the ‘complete’ cohort approach for 
patients diagnosed 2000-2007 (with follow-up to 2008) stratified by gender and age-
group (i.e. 15-44, 45-54, 55-64, 65-74, 75 years or older) as previously described [15]. 
Age standardised survival [16] and European average estimates [15] are also provided. 
Survival trends were estimated for countries with cases diagnosed between 1999 and 
2007 (n=24 countries) with follow-up to 2008, using the ‘period’ approach [17] to 
reliably predict 5-year survival in the years, 1999-2001, 2002-2004, and 2005-2007. 
 
Results 
Oesophageal, stomach and small intestine cancers were more common in men than 
women, Table 1. Some countries in Eastern Europe had a high percentage of DCO cases. 
Elsewhere in Europe the highest DCO rates were reported in Germany. Mean age at 
diagnosis for oesophageal, stomach and small intestine cancers ranged from 60.7-71.6, 
66.8-73.1 and 60.5-68.9 years, respectively, Table 1. 
 
Oesophageal cancer 
European average 1-year age-standardised RS was 39.9%, with 12.4% of patients 
surviving 5-years, Figure 1. Patients in the Central Europe region, particularly Belgium, 
had the best survival in Europe while survival was poorest in Eastern Europe. Lithuania 
and Bulgaria had the lowest 5-year RS estimates. Conditional 5-year survival displayed 
less heterogeneity across Europe, Figure 1. 
 
Survival, at all follow-up time points investigated, decreased with increasing age, Figure 
1. One-, 3- and 5-year age-standardised RS was higher in women than men across all 
follow-up time points, Figure 1. 
 
Overall oesophageal cancer 5-year age-standardised patient survival improved from 9.9% 
to 12.6% between 1999-2001 and 2005-2007. Graphs of 5-year RS by region and Europe 
overall are presented in Supplement 1. The largest regional improvements in 5-year RS 
were observed in Ireland and UK and Central Europe with limited improvements 
observed in Eastern or Southern Europe, (Table 2 and Supplement 1). Similar 
improvements in patient survival were noted between 1999-2001 and 2002-2004, and 
between 2002-2004 and 2005-2007 for most regions.  
 
Stomach Cancer  
One-year age-standardised RS for stomach cancer patients reached almost 50% with 
substantial regional variation, see Figure 2. While the Eastern Europe region had the 
poorest 1-year RS (38.4%), the 5-year RS was lowest in Ireland and UK (17.2%) region, 
with similar survival across all UK countries. Southern Europe had the best 5-year patient 
survival (29.6%) in Europe. While Eastern Europe had low 1- and 5-year RS, 5-year 
conditional survival was better than in Northern Europe, and Ireland and UK. Wide 
variation among countries was identified in 5-year RS estimates from 11.9% in Bulgaria 
to 34.5% in Iceland. Survival, at all follow-up time points investigated, decreased with 
increasing age, and women appeared to fare better than men. 
 
Overall 5-year patient survival increased absolutely by less than 2% points across Europe 
between 1999-2001 and 2005-2007 (Table 3 and Supplement 2). The most marked 
improvement in patient survival was in Slovenia from 1999-2001 (RS 20.8%) to 2002-
2004 (RS 27.1%), Table 3. Although no change was observed in 5-year RS in Northern 
Europe, improved patient survival was evident in Denmark and Sweden with a decrease 
in 5-year RS observed in Finland. The Netherlands had low RS compared to the rest of 
Central Europe across all periods. 
 
Southern and Central Europe had better patient survival for cardia and non-cardia cancers 
than other regions, Table 4. Survival for non-cardia cancer patients was significantly 
higher than for cardia cancer patients, Table 4. In Eastern Europe, as in Southern and 
Central Europe, patients with non-cardia cancer predominated, Table 4. 
 
Small Intestine Cancer  
Small intestine cancer 1- and 5-year RS was 67.9% and 47.9%, respectively, see Figure 3. 
Ireland and UK was the region with the worst 1-year patient survival at 58.8%. Croatia 
was the country with the poorest 1-year RS (53.3%). The Central Europe region had the 
best 5-year RS for small intestine cancer (53.9%) with the poorest in the Ireland and UK 
region (36.9%). Wide country variation was identified in 5-year RS from 23.5% in Malta 
to 58.6% in Switzerland. Five-year conditional survival in patients in Ireland and UK 
remained significantly below the European average, Figure 3. 
 
European patient survival declined with increasing age. Overall 1-, 3- and 5-year age-
standardised RS were slightly higher in women compared to men; particularly evident in 
younger patients, Figure 3. 
 
Overall 5-year RS increased from 40.5% to 48.7% from 1999-2001 until 2005-2007 
(Table 5 and supplement 3). The largest improvements (>10% points) in patient survival 
were observed in Italy, Austria, Czech Republic and Finland. All regions, except Ireland 
and UK, showed a significant increase in survival from 1999-2001 to 2005-2007. 
 
Discussion 
European wide variation in patient survival was observed for all three cancer sites 
investigated between regions. Country-specific patient survival also displayed wide 
variation with several countries showing inconsistent estimates to their region, including 
Denmark, the Netherlands, Bulgaria and Croatia. Survival of patients improved modestly 
from 1999-2001 until 2005-2007 for all cancer sites. Oesophageal and stomach cancer 5-
year RS for Europe remained very poor. Small intestine cancer had the best overall 5-year 
RS in Europe and displayed the largest improvement in patient survival. 
 
Oesophageal cancer 
European 1- and 5-year RS for oesophageal cancer patients remained poor (35.8% and 
10.6%, respectively). With the exception of Central Europe, which maintained the highest 
patient survival compared with other European regions as reported in EUROCARE-4 
[18], RS in other European regions remained below that reported in the USA [19]. 
Eastern Europe, where OSCC predominates, continued to have the worst RS. 
Geographical differences in the proportion of oesophageal cancer patients with histology 
‘not otherwise specified’ between regions may account for some of these disparities (data 
not shown). Additionally, differences in diagnostic accuracy may also account for 
regional variation with potential misclassification of gastro-oesophageal tumours [20,21]. 
Cancer stage is a major predictor of cancer patient survival and differences in stage 
distribution between countries and regions, as a result of early detection and/or diagnostic 
practices, could also account for some of the observed disparity seen in Eastern Europe 
[22,23]. 
Five-year RS for oesophageal cancer patients, for Europe as a whole, increased 
marginally from 9.8% in 1999-2001 to 12.6% in 2005-2007. Central Europe and Ireland 
and UK demonstrated the most marked improvement. This may be explained by 
improvements in surgical techniques, adjuvant therapy, earlier diagnosis and/or 
centralisation of treatment. The trends in Europe in mortality [24] and incidence [25] in 
oesophageal cancer vary markedly across the countries in the study, but generally there is 
tight correlation between them, suggesting that improvements in survival are not due to 
over-diagnosis arising from increased surveillance. Variation in incidence trends may be 
caused by regional changes in the risk-factor prevalence [26]. Obesity may be increasing 
the incidence of OAC particularly in northern and western Europe, while reduction in 
tobacco and alcohol consumption is reducing the incidence of OSCC [26]. The generally 
better prognosis of patients diagnosed with EAC is not consistent across Europe [18]. 
 
Centralisation of treatment has produced a marked improvement in oesophageal cancer 
patient survival with many European countries introducing such strategies in recent years. 
Ireland and UK demonstrated comparatively better patient survival improvements for 
oesophageal cancer than most Northern European countries in both time frames 
investigated and in line with the centralisation of cancer services for oesophagogastric 
cancer surgery implemented in the UK in 2001. While hospitals performing more than 40 
oesophagectomies annually had lower 30-day postoperative mortality, this may not fully 
explain regional differences in oesophageal or gastric cancer patient survival [27]. Other 
factors, as highlighted by the International Benchmarking Partnership, may be important 
such as late diagnosis, differences in public awareness of cancer symptoms, cancer stage, 
morphology and topography, presence of co-morbidities, lifestyle factors such as cigarette 
smoking, and access to optimum care [28]. Body mass index has also been shown to be a 
prognostic marker for OSCC [29]. The fact that 5-year conditional patient survival is 
rather similar across Europe indicates relevant differences in short term mortality and 
points towards early diagnosis and access to care as important areas to consider with 
regards to improvement of oesophageal cancer patient treatment and standardisation of 
care. 
 
Stomach cancer  
One- and 5-year RS for stomach cancer patients remained low particularly in comparison 
to 5-year survival of around 69% achieved in Asia [30]. Compared to Europe, stomach 
cancer incidence in Asia is high, with a predominance of non-cardia tumours which have 
better patient survival [31]. Screening programs and more aggressive treatment 
undoubtedly contribute to the superior survival of patients seen in Asia but similar 
strategies are unlikely to be cost-effective in comparatively low incidence countries 
within Europe. Histological and staging variability across Europe may account for some 
of the differences in stomach cancer patient survival observed between countries. Patient 
survival improved overall in Europe from 1999-2001 to 2005-2007 particularly in 
Denmark and the Czech Republic. Both mortality [20] and incidence [32] rates for 
stomach cancer continue to fall for most countries during the period of this study, 
suggesting no appreciable surveillance-driven over-diagnosis that could compromise 
estimated survival improvement. A recent report using data from the World Health 
Organisation reported lower stomach cancer mortality from 2000 onwards in the UK, the 
USA, Japan and several European countries [33]. Centralisation of treatment for gastric 
cancer was implemented in several European countries, including the UK, Denmark and 
the Netherlands, in recent years despite reports of no survival benefit [27,34] for patients. 
While 5-year RS was worst in Ireland and UK, improvements in the most recent time 
period were observed particularly in Wales and England. While delayed diagnosis, first 
line treatment, or post-operative mortality could explain the patient survival disadvantage 
in Ireland and UK, other factors appear to be important given the poor 5-year conditional 
patient survival. Lifestyle differences such as smoking behaviour, co-morbidities, cancer 
stage and/or subtype could explain the variability observed across countries.  
 
The decreasing 5-year RS in Finland and Norway could be related to the marked decrease 
in incidence, mainly affecting distal stomach cancer [35], in these countries. Patients with 
distal stomach cancer have better prognosis, as presented in this report, and this cancer is 
more responsive to preventative measures than cancers arising in the cardia or proximal 
stomach. As an effect of this selective incidence decrease, patient with proximal cancers, 
who carry a worse prognosis, may have become relatively more frequent over time.  
 
Small intestine cancer 
European 1- and 5-year RS for patients with epithelial small bowel carcinomas diagnosed 
from 1978-2002 were comparatively lower than those reported here for all small intestine 
cancers, excluding lymphomas [14]. Incidence of epithelial small intestine cancers are 
similar in Ireland and UK and Northern and Southern Europe [14] despite variation in RS. 
Differences in cancer stage at diagnosis and subtype throughout Europe could explain the 
reported variations in patient survival. The EUROCARE-5 data encompasses all small 
intestine cancer histologies with the exception of lymphomas. Small intestine sarcomas 
reportedly have worse prognosis than neuroendocrine cancers which have a more 
favourable outcome [8,36]. Small intestine cancers are notoriously difficult to diagnose 
due to their vague symptoms. Delays in diagnosis and treatment of small intestine cancer 
patients are associated with poorer prognosis [37]. One-year RS was lower in Ireland and 
UK as previously reported [14], and also in Denmark and several Eastern European 
countries, suggesting that delayed diagnosis, at patient, primary care or referral stages, 
might be an important factor. This would not however explain the poorer 5-year 
conditional survival estimates in Ireland and UK, Denmark and Malta for those patients 
who survived the first year post diagnosis. 
 
Improved survival is reported across all European regions particularly in Northern, 
Central and Eastern Europe for small intestine cancer patients. Increasing trends in small 
intestine cancer incidence has been reported [11,12,13,38,39] but mortality rates have 
remained stable or slightly increasing [38,39]. Given the low incidence and mortality 
rates, and the heterogeneity of tumour types, it is difficult to say whether effective therapy 
has increased patient survival [40]. Recent improvements in treatment of small intestine 
sarcomas, with the use of tyrosine kinase inhibitors since 2001 [41] may have influenced 
patient survival. Due to the low incidence of gastrointestinal stromal tumours [42], a rare 
sarcoma sub-type, the effect on patient survival in large datasets like EUROCARE is 
difficult to measure without ad hoc analyses. 
 
Detailed discussion of the strengths and limitations of the EUROCARE-5 data are 
available in the article by Rossi et al. in this issue [15]. Increasing survival trends after 5 
years of follow-up were found in patients with poor prognosis cancer and aged 75 year 
and older for Austria, Croatia, Germany, Poland and Slovakia, and may be related to 
difficulties in the ascertainment of life status [43] or to DCO proportions [15]. Survival 
estimates from these countries should be interpreted with caution. However, comparing 
individual countries may provide more meaningful assessment of reasons for disparities 
in patient survival; this is limited, however, for cancers with low incidence estimates such 
as small intestine and oesophageal cancer as the standard errors become large. In 
addition, the % DCO statistic for each country and cancer are available in Table 1, and 
should inform comparisons being made between individual countries’ patient survival 
estimates [44]. 
 
Conclusions 
This article presents overall patient survival for three anatomical sub-sites: oesophagus, 
stomach and small intestine. They provide some indication of areas that need further 
investigation to determine the drivers of the variation in survival of cancer patients across 
Europe. More in-depth investigation by anatomic sub-site and histology could explain the 
variability observed and are planned using additional data from EUROCARE-5. The 
historic nature of these large collaborative studies means that recent developments in 
early detection, routes to treatment, changes to service provision and new treatment 
modalities for patients will have had insufficient time to have a visible effect. Continued 
monitoring of cancer survival across Europe will allow further evaluation of survival 
differences to further promote the widespread application of effective diagnosis and 
treatment modalities [45]. In summary, although improvements in survival have been 
reported for cancers of the oesophagus, stomach and small intestine, survival remains 
poor with wide variation across Europe. 
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Table 1: Number of cases, percentage Death Certificate Only (DCO) cases and mean age at diagnosis (years) for oesophageal, stomach and small 
intestine cancers by country/region before exclusion of autopsy and DCO cases. 
 
Oesophagus Stomach Small Intestine 
 
All 
cases Men Women 
% 
DCO
a
 
Mean 
age 
All 
cases Men Women 
% 
DCO
a 
Mean 
age 
All 
cases Men Women 
% 
DCO
a 
Mean 
age 
Northern EU 
               Denmark 3,177 2,242 935 0 68.2 4,200 2,700 1,500 0 68.7 602 303 299 0 66.7 
Finland 1,859 1,218 641 1.1 69.2 5,812 3,213 2,599 0.7 70.1 691 367 324 1.4 65.3 
Iceland 121 87 34 0 71.6 281 171 110 0 72.5 47 27 20 0 66.2 
Norway 1,466 1,041 425 0.8 70.1 4,521 2,717 1,804 0.6 72.5 836 441 395 0.2 66.9 
Sweden 3,203 2,300 903 0 70.1 7,863 4,740 3,123 0 72.1 1,819 1,012 807 0 68.9 
Ireland and UK 
               Ireland 2,706 1,707 999 0.8 69.7 3,701 2,297 1,404 1.6 69.8 392 228 164 1.5 65.3 
UK-England 50,610 32,299 18,311 2.6 71.5 55,973 36,023 19,950 3.5 72.9 5,501 2,985 2,516 2.5 68.1 
UK-Northern 
Ireland 1,294 817 477 0.7 69.9 1,882 1,129 753 1.3 71.5 189 109 80 1.1 65.7 
UK-Scotland 6,531 4,072 2,459 0.4 70.7 6,771 4,096 2,675 0.5 72.0 615 313 302 0.2 67.5 
UK-Wales 3,530 2,196 1,334 2.4 71.2 4,324 2,706 1,618 3.8 73.1 413 210 203 1.9 68.2 
Central  EU 
               Austria 2,569 2,066 503 0 64.7 10,572 5,817 4,755 0 71.1 889 463 426 0 66.2 
Belgium
b
 3,984 3,054 930 0 66.3 6,737 4,146 2,591 0 71.6 856 457 399 0 66.6 
France
b
 4,531 3,817 714 0 65.9 6,194 3,961 2,233 0 71.3 822 462 360 0 66.8 
Germany
b
 10,152 8,021 2,131 10.6 65.3 31,664 17,865 13,799 15.6 70.9 2,357 1,254 1,103 8.2 66.4 
Switzerland
b
 1,222 936 286 1.0 68.0 2,223 1,317 906 1.7 70.3 381 213 168 0 68.1 
The Netherlands 11,654 8,355 3,299 0 67.6 16,208 10,268 5,940 0 69.9 1,769 920 849 0 66.0 
Southern  EU 
               Croatia 1,815 1,492 323 7.6 64.9 9,146 5,553 3,593 8.2 68.6 306 173 133 6.5 66.1 
Italy
b
 5,600 4,178 1,422 1.5 68.9 36,113 20,960 15,153 1.6 72.6 2,248 1,259 989 1.2 68.6 
Malta 94 69 25 8.5 68.2 359 216 143 5.0 70.0 31 13 18 3.2 60.5 
Portugal
b
 2,619 2,201 418 0.1 63.7 14,723 8,931 5,792 0.1 67.2 641 366 275 0 66.3 
Slovenia 739 607 132 2.3 64.9 3,772 2,314 1,458 2.4 68.9 162 95 67 0 65.1 
Spain
b
 1,782 1,541 241 2.6 65.1 6,598 4,193 2,405 3.6 70.4 378 225 153 1.3 67.2 
Eastern  EU 
               
Bulgaria 1,478 1,152 326 22.5 64.6 14,616 9,005 5,611 20.5 68.2 345 197 148 24.1 63.5 
Czech Republic 3,680 3,090 590 5.1 63.6 13,760 7,996 5,764 4.6 69.3 1,019 559 460 3.9 65.4 
Estonia 434 355 79 0 64.9 3,277 1,776 1,501 0.2 66.8 90 36 54 0 64.2 
Latvia 881 739 142 6.5 63.8 5,324 2,948 2,376 6.6 67.0 114 52 62 11.4 65.8 
Lithuania 1,180 1,022 158 4.8 63.1 7,047 4,095 2,952 4.2 67.2 176 83 93 8.5 65.8 
Poland
b
 1,353 1,070 283 1.7 63.5 6,253 3,938 2,315 1.6 67.0 230 122 108 0 64.3 
Slovakia 1,937 1,732 205 12.5 60.7 6,826 4,111 2,715 12.3 6\8.1 397 212 185 10.8 64.3 
a Also includes ‘autopsy-only’ basis of diagnosis. b Pooled rates as these countries did not have national coverage. 
Table 2: Five-year relative survival (RS) and corresponding 95% confidence interval (CI) of oesophageal cancer in three periods (1999-
2001, 2002-2004, 2005-2007) by country, European region and European average, with p-values of differences
a
 between periods.  
 
Number of cases 
analysed across 
all time periods 
1999-2001 2002-2004 2005-2007 
2005-2007  
vs 1999-2001 
 
 % RS 95% CI % RS 95% CI % RS 95% CI Abs diff p-value 
Europe 111006 9.9  (9.3-10.5) 11.7 (11.0-12.3) 12.6 (12.0-13.2) 2.7 <0.001 
Northern EU 10471 9.1 (8.0-10.4) 11.3 (10.1-12.8) 10.8 (9.7-12.1) 1.7 0.023 
Denmark  3401 4.6  (3.3-6.4) 9.0 (7.0-11.5) 9.7 (7.9-11.8) 5.1 <0.001 
Finland  1959 9.6  (7.2-12.7) 12.9 (9.9-16.7) 12.1 (9.5-15.2) 2.5 0.108 
Iceland
 b
 129 - 
 
- - - - - - 
Norway  1572 8.4 (5.7-12.4) 12.5 (9.5-16.5) 10.9 (8.0-14.8) 2.5 0.150 
Sweden  3411 13.3 (11.0-16.0) 12.3 (10.0-15.2) 10.6 (8.8-12.8) 2.7 0.052 
Ireland and UK 67862 10.3 (9.8-10.8) 11.9 (11.4-12.4) 13.5 (13.0-14.1) 3.2 <0.001 
Ireland 2816 11.9 (9.6-14.7) 15.3 (12.7-18.3) 16.7 (14.2-19.6) 4.8 0.005 
England  52786 9.9 (9.4-10.6) 11.5 (10.9-12.1) 13.7 (13.1-14.3) 3.7 <0.001 
Northern Ireland
 b
   1389 9.6 (7.1-13.0) 14.6 (11.3-18.7) - - - - 
Scotland  7142 10.0 (8.6-11.6) 11.7 (10.1-13.5) 11.1 (9.7-12.7) 1.1 0.157 
Wales  3727 14.1 (11.7-17.1) 13.8 (11.6-16.4) 12.6 (10.5-15.0) 1.6 0.188 
Central  EU 18139 10.8 (9.9-11.8) 13.9 (12.8-15.0) 15.2 (14.2-16.2) 4.3 <0.001 
Austria 2711 11.7 (9.4-14.6) 17.9 (15.1-21.2) 17.1 (14.6-20.0) 5.4 0.002 
France 3365 13.0 (11.2-15.0) 11.2 (9.6-13.0) - - - - 
Germany
 b
 1804 16.1 (12.8-20.4) 13.7 (10.6-17.7) - - - - 
Switzerland 1075 15.3 (11.4-20.5) 18.3 (14.3-23.4) 18.9 (14.6-24.4) 3.6 0.145 
The Netherlands   11744 9.6 (8.6-10.8) 13.1 (11.9-14.5) 14.4 (13.3-15.7) 4.8 <0.001 
Southern  EU 4474 9.7 (8.2-11.6) 10.6 (9.0-12.5) 10.9 (9.2-12.7) 1.1 0.186 
Italy 3278 10.7 (8.8-13.2) 12.4 (10.3-14.8) 11.0 (9.1-13.3) 0.3 0.432 
Malta
 b
   67 - - - - - - - - 
Slovenia
 b
 805 7.1 (4.2-12.1) - - 8.6 (5.5-13.6) 1.5 0.289 
Spain 1792 7.9 (6.1-10.2) 7.9 (6.1-10.2) - - - - 
Eastern  EU 10063 7.3 (6.1-8.6) 7.4 (6.3-8.6) 8.1 (7.0-9.3) 0.8 0.175 
Bulgaria
 b
 1172 - - - - 6.7 (4.2-10.7) - - 
Abs = absolute, Diff = Difference. 
a 
Survival differences between periods have been assessed by the Z-test. 
b
 Standardized Survival rates could not be calculated where one or more age specific rates are absent due to small number of cases. 
Note: % difference is the relative difference.   
Note: Empty fields of RS in France and Spain in 2007 are due to a limitation of analysis to periods 1999-2001 and 2002-2004 only. 
 
Czech Republic  3496 7.3 (5.4-9.8) 9.2 (7.0-12.2) 11.4 (9.5-13.7) 4.2 0.003 
Estonia
 b
 485 - - - - - - - - 
Lithuania
 b
 1348 8.4 (5.6-12.5) 4.7 (2.9-7.5) - - - - 
Poland
 b
 1474 8.1 (5.3-12.4) 7.7 (5.3-11.3) 6.2 (4.0-9.7) 1.9 0.205 
Slovakia
 b
 111006 6.4 (3.9-10.3) 10.1 (6.4-15.6) - - - - 
 
Table 3: Five-year relative survival (RS) and corresponding 95% confidence interval (CI) of stomach cancer in three periods (1999-2001, 
2002-2004, 2005-2007) by country, European region and European average, with p-values of differences
a 
 between periods. 
 
Number of cases 
analysed across 
all time periods 
1999-2001 2002-2004 2005-2007 
2005-2007  
vs 1999-2001 
 
% RS 95% CI % RS 95% CI % RS 95% CI Abs diff p-value 
Europe 232452 23.3 (22.9-23.8) 23.8 (23.4-24.3) 25.1 (24.6-25.6) 1.8 <0.001 
Northern EU 26201 22.4 (21.4-23.5) 21.7 (20.7-22.7) 22.7 (21.6-23.8) 0.3 0.360 
Denmark  4691 14.0 (12.2-16.2) 14.7 (12.7-16.9) 18.3 (16.3-20.6) 4.3 0.002 
Finland  6667 28.5 (26.5-30.8) 25.0 (23.0-27.1) 25.2 (23.1-27.5) -3.3 0.016 
Iceland
 b
 341 - - - - - - - - 
Norway  5341 23.5 (21.2-26.1) 21.8 (19.6-24.3) 23.5 (21.1-26.2) 0.0 0.499 
Sweden  9152 21.4 (19.8-23.2) 22.6 (20.8-24.5) 22.5 (20.7-24.4) 1.0 0.214 
Ireland and UK 83908 16.1 (15.6-16.7) 16.5 (16.0-17.1) 18.2 (17.6-18.8) 2.0 <0.001 
Ireland  4056 19.4 (17.1-22.0) 19.4 (17.0-22.0) 21.9 (19.4-24.6) 2.5 0.086 
England  64533 16.1 (15.5-16.7) 16.3 (15.7-16.9) 18.0 (17.3-18.7) 1.9 <0.001 
Northern Ireland  2189 17.7 (14.7-21.4) 18.8 (15.8-22.4) 18.4 (15.0-22.5) 0.6 0.400 
Scotland  7992 14.7 (13.1-16.5) 16.8 (15.1-18.7) 16.3 (14.5-18.3) 1.6 0.104 
Wales  5144 16.1 (13.9-18.6) 16.5 (14.3-18.9) 20.0 (17.5-22.9) 4.0 0.015 
Central  EU 39365 24.0 (23.2-24.9) 24.7 (23.9-25.6) 26.2 (25.3-27.1) 2.1 <0.001 
Austria  12740 30.7 (29.1-32.3) 29.8 (28.2-31.5) 33.6 (31.8-35.4) 2.9 0.009 
France
 b
 4997 25.4 (23.4-27.5) 28.1 (26.1-30.3) - - - - 
Germany  4486 27.2 (24.7-30.0) 27.0 (24.5-29.7) 27.5 (24.9-30.3) 0.3 0.439 
Switzerland  2019 25.0 (21.6-29.0) 29.3 (25.5-33.7) 31.4 (27.4-36.0) 6.4 0.014 
The Netherlands   18808 18.9 (17.8-20.1) 20.6 (19.4-21.8) 21.1 (19.9-22.3) 2.2 0.005 
Southern  EU 29234 30.5 (29.4-31.6) 30.4 (29.4-31.5) 32.1 (31.0-33.3) 1.6 0.021 
Italy pool 23784 32.7 (31.5-34.0) 31.6 (30.4-32.9) 33.8 (32.5-35.1) 1.1 0.126 
Malta
 b
  398 - - - - - - - - 
Slovenia  4116 20.8 (18.5-23.5) 27.1 (24.4-30.1) 27.9 (25.3-30.7) 7.0 <0.001 
Spain  6569 25.1 (23.5-26.8) 25.9 (24.2-27.7) - 
 
- - 
Eastern  EU 53747 17.6 (16.9-18.2) 19.0 (18.3-19.6) 18.8 (18.2-19.5) 1.3 0.004 
Bulgaria  12555 10.9 (9.8-12.1) 12.5 (11.3-13.8) 12.8 (11.7-14.0) 2.0 0.010 
Czech Republic  14449 18.1 (16.9-19.4) 21.3 (19.9-22.7) 22.6 (21.2-24.0) 4.4 <0.001 
Estonia  3852 21.8 (19.3-24.7) 24.8 (22.0-27.8) 22.2 (19.6-25.1) 0.3 0.432 
Lithuania  8614 22.0 (20.4-23.8) 23.4 (21.7-25.2) 23.7 (21.7-25.8) 1.7 0.112 
Poland  7164 15.2 (13.5-17.0) 16.7 (15.0-28.5) 15.6 (14.0-17.4) 0.4 0.367 
Slovakia  7186 21.2 (19.3-23.2) 20.3 (18.6-22.3) 21.1 (19.2-23.1) -0.1 0.471 
Abs = absolute, Diff = Difference. 
a
 Survival differences between periods have been assessed by the Z-test. 
b
 Standardized Survival rates could not be calculated where one or more age specific rates are absent due to small number of cases. 
Note: % difference is the relative difference.   
Note: Empty fields of RS in Spain in 2007 are due to a limitation of analysis to periods 1999-2001 and 2002-2004 only. 
 
Table 4: Age-standardised 1-year, 5-year relative survival, and 5-year relative survival conditional on surviving 1 year, with 95% confidence 
intervals, for cardia and non-cardia stomach cancers. 
 
Cardia Non-cardia 
No. of 
 cases 
1-year 5-year Conditional No. of 
 cases 
1-year 5-year Conditional 
% RS 95% CI % RS 95% CI % RS 95% CI % RS 95% CI % RS 95% CI % RS 95% CI 
Europe 48611 46.0 45.5-46.4 16.0 15.5-16.4 34.0 33.2-34.9 96020 54.6 54.3-54.9 30.5 30.1-30.9 66.3 65.9-66.8 
Northern EU 5299 43.3 41.9-44.7 14.1 12.9-15.3 32.5 30.0-35.1 6027 55.2 53.8-56.5 28.6 27.1-30.2 51.9 49.4-54.5 
Denmark  1687 41.0 38.6-43.4 12.8 10.8-15.0 31.2 26.8-36.2 1149 48.0 44.9-51.0 25.9 22.8-29.2 53.9 48.4-60.1 
Finland  936 45.9 42.5-49.2 16.0 13.2-19.1 34.9 29.5-41.4 272 57.8 51.3-63.7 - - - - 
Iceland
 
 41 31.0 18.0-44.8 10.3 3.4-19.1 33.2 15.2-72.5 70 74.7 62.7-83.0 - - - - 
Norway  967 43.9 40.6-47.1 15.4 12.7-18.5 35.2 29.6-42.0 1831 58.0 55.4-60.5 30.0 27.2-32.9 51.8 47.7-56.2 
Sweden  1668 44.2 41.7-46.6 13.6 11.6-15.7 30.7 26.6-35.5 2705 55.9 53.7-58.0 28.0 25.6-30.4 50.1 46.3-54.1 
Ireland and UK 19244 46.6 45.8-47.3 14.4 13.8-15.1 31.0 29.7-32.4 17457 48.4 47.5-49.3 23.2 22.3-24.0 47.9 46.3-49.5 
Ireland  986 42.2 39.0-45.3 17.0 14.1-20.0 40.2 34.3-47.1 1705 46.2 43.8-48.7 24.4 21.9-27.0 52.8 48.3-57.7 
England  14510 47.4 46.5-48.2 14.8 14.1-15.5 31.2 29.8-32.70 11932 49.2 48.1-50.3 23.1 22.0-24.2 46.9 45.1-48.9 
Northern Ireland  462 46.4 41.6-51.1 16.2 12.3-20.7 35.0 27.5-44.5 534 42.2 37.4-47.0 21.2 16.9-25.8 50.1 41.9-59.9 
Scotland  1983 42.9 40.5-45.3 11.3 9.6-13.2 26.4 22.7-30.7 1787 47.6 44.9-50.2 23.4 20.8-26.1 49.2 44.6-54.4 
Wales  1303 46.7 43.8-49.6 13.2 10.9-15.8 28.4 23.8-33.8 1499 47.3 44.2-50.4 22.3 19.4-25.4 47.2 41.9-53.1 
Central  EU 13230 49.2 48.4-50.1 18.2 17.4-19.0 37.0 35.4-38.5 26709 60.9 60.3-61.5 36.0 35.2-36.7 59.1 58.0-60.1 
Austria  1297 50.5 47.7-53.3 22.6 19.8-25.5 44.7 39.9-50.1 1895 65.9 63.5-68.1 40.2 37.3-43.1 61.0 57.3-65.0 
Belgium 1264 55.9 53.1-58.7 20.5 17.7-23.5 36.7 32.1-41.9 1504 63.0 60.3-65.7 35.6 32.3-38.8 56.4 52.0-61.2 
France
 
 1384 50.6 47.9-53.3 14.7 12.6-17.0 29.0 25.3-33.4 2949 58.6 56.6-60.6 32.8 30.6-35.0 56.0 52.9-59.2 
Germany  4506 52.7 51.2-54.2 22.3 20.7-23.9 42.3 39.7-45.1 11906 64.4 63.5-65.3 40.1 39.0-41.3 62.3 60.8-63.9 
Switzerland  494 52.0 47.4-56.5 - - - - 1145 64.1 61.1-67.0 40.8 37.2-44.3 63.6 59.1-68.4 
The Netherlands   4285 42.4 40.9-43.9 13.1 11.9-14.5 31.0 28.3-34.0 7310 53.7 52.5-54.9 28.9 27.5-30.2 53.8 51.6-56.0 
Croatia 476 42.43 37.7-47.1 27.0 21.9-32.4 63.7 54.2-74.9 446 56.6 51.6-61.4 37.4 31.4-43.5 66.1 57.6-75.8 
Southern  EU 5793 48.6 47.2-49.9 20.2 18.9-21.5 41.5 39.2-44.0 24960 60.1 59.4-60.7 36.2 35.5-36.9 60.2 59.2-61.3 
Italy  3193 52.2 50.3-54.0 20.9 19.1-22.7 40.0 37.0-43.3 15728 61.3 60.5-62.1 37.1 36.2-38.1 60.6 59.2-61.9 
Malta
 
 65 35.9 25.5-46.4 - - - - 107 49.2 38.8-58.7 25.4 16.9-34.8 51.7 38.6-69.3 
Portugal 890 45.5 42.0-48.9 20.6 17.6-23.9 45.4 39.7-51.9 4188 59.4 57.8-60.9 36.1 34.4-37.9 60.8 58.4-63.4 
Slovenia  473 46.2 41.4-50.8 18.3 14.1-22.9 39.6 31.8-49.3 1424 61.2 58.6-63.8 41.0 37.8-44.2 67.0 62.8-71.5 
Spain  696 44.7 40.8-48.5 16.9 13.9-20.2 37.9 32.0-44.8 3067 55.4 53.5-57.2 30.8 28.9-32.7 55.6 52.7-58.5 
Eastern  EU 5045 36.4 35.1-37.8 13.1 12.0-14.4 36.1 33.2-39.2 20867 45.6 44.9-46.3 23.7 23.0-24.4 52.0 50.6-53.4 
Bulgaria  1273 25.3 22.9-27.8 7.6 5.8-9.9 30.2 23.5-38.7 6460 33.8 32.6-35.0 14.2 13.1-15.4 42.0 39.1-45.2 
Czech Republic  1596 41.4 38.9-43.9 15.6 13.4-18.0 37.7 32.9-43.2 5927 49.5 48.2-50.9 27.5 26.0-29.0 55.5 53.0-58.1 
Estonia  262 41.2 35.0-47.3 18.4 12.9-24.7 44.7 33.6-59.3 1760 50.9 48.4-53.2 29.1 26.3-31.8 57.2 52.7-62.0 
Latvia 266 32.8 27.0-38.7 15.9 10.8-21.9 48.4 35.8-65.5 1012 44.1 40.9-47.3 22.8 19.4-26.3 51.7 45.2-59.0 
Lithuania  312 42.2 36.3-47.9 15.4 11.2-20.3 36.6 28.0-47.6 2218 54.6 52.4-56.7 31.3 28.8-33.7 57.3 53.5-61.3 
Poland  627 41.6 37.7-45.5 12.8 9.6-16.5 30.8 23.9-39.6 398 47.9 42.8-52.9 17.4 12.6-22.9 36.4 27.5-48.1 
Slovakia  709 38.9 35.1-42.7 13.6 10.5-17.0 34.8 28.0-43.3 3092 53.9 52.0-55.7 28.7 26.7-30.7 53.2 50.1-56.5 
 
Table 5: Five-year relative survival (RS) and corresponding 95% confidence interval (CI) of small intestine cancer in three periods (1999-
2001, 2002-2004, 2005-2007) by country, European region and European average, with p-values of differences* between periods. 
 
Number of cases 
analysed across 
all time periods 
1999-2001 2002-2004 2005-2007 
2005-2007 
vs 1999-2001 
 
% RS 95% CI % RS 95% CI % RS 95% CI Abs diff p-value 
Europe 18116 40.5 (38.5-42.7) 45.8 (43.9-47.9) 48.7 (46.9-50.5) 8.1 <0.001 
Northern EU 4021 49.9 (46.7-53.3) 50.7 (47.7-53.9) 55.8 (53.0-58.8) 6.0 0.004 
Denmark  626 37.4 (30.3-46.1) 37.7 (30.4-46.6) 39.6 (33.2-47.1) 2.2 0.341 
Finland  678 51.7 (43.7-61.2) 55.4 (48.8-62.9) 62.1 (54.9-70.3) 10.4 0.040 
Iceland
 b
 49 - - - - - - - - 
Norway  834 52.6 (45.7-60.6) 51.6 (45.4-58.6) 56.6 (50.5-63.3) 3.9 0.216 
Sweden  1835 52.0 (47.5-57.0) 53.3 (48.9-58.1) 59.5 (55.3-64.0) 7.5 0.011 
Ireland and UK 7178 35.3 (33.1-37.6) 36.1 (34.1-38.3) 37.7 (35.7-39.8) 2.4 0.058 
Ireland  376 35.5 (26.2-48.1) 44.7 (36.3-55.2) 42.8 (34.7-52.9) 7.3 0.154 
England  5539 34.4 (31.9-37.0) 35.1 (32.8-37.5) 37.7 (35.5-40.2) 3.4 0.027 
Northern Ireland  230 37.4 (27.9-50.2) 33.9 (23.0-50.0) 43.5 (30.6-61.9) 6.1 0.263 
Scotland  639 39.6 (32.7-48.0) 37.5 (30.1-46.7) 38.4 (31.9-46.1) -1.3 0.405 
Wales  401 38.9 (28.6-52.7) 38.2 (29.6-49.3) 33.3 (25.9-42.8) -5.6 0.227 
Central  EU 3399 44.1 (40.7-47.8) 47.8 (44.5-51.2) 53.0 (50.0-56.3) 9.0 <0.001 
Austria  899 43.6 (37.3-50.9) 52.3 (46.0-59.4) 55.7 (50.1-61.9) 12.1 0.004 
France  572 45.3 (39.3-52.3) 48.3 (42.2-56.2) - - - - 
Germany  323 42.0 (31.6-56.0) 45.6 (34.9-59.6) 50.1 (41.2-61.0) 8.1 0.154 
Switzerland  294 54.7 (45.0-66.5) 59.9 (50.4-71.0) 55.4 (45.4-67.5) 0.7 0.467 
The Netherlands   1737 44.5 (39.6-50.0) 43.3 (39.0-48.2) 51.5 (47.2-56.3) 7.1 0.022 
Southern  EU 1570 39.5 (34.7-44.9) 49.0 (44.3-54.2) 49.7 (45.5-54.3) 10.2 0.001 
Italy  1338 38.7 (33.5-44.6) 48.7 (43.7-54.4) 51.1 (46.4-56.3) 12.5 <0.001 
Malta
 b
 34 - - - - - - - - 
Slovenia
 b
 153 - - 48.5 (33.8-69.6) - - - - 
Spain  347 46.3 (38.4-56.0) 42.4 (35.9-50.1) - - - - 
Eastern  EU 1951 34.5 (29.4-40.4) 43.4 (38.9-48.4) 43.5 (39.6-47.8) 9.1 0.005 
Bulgaria  248 41.9 (26.0-67.6) 35.8 (25.1-51.0) - - - - 
Abs = absolute, Diff = Difference. 
a
 Survival differences between periods have been assessed by the Z-test. 
b
 Standardized Survival rates could not be calculated where one or more age specific rates are absent due to small number of cases. 
Note: % difference is the relative difference.   
Note: Empty fields of RS in France and Spain in 2007 are due to a limitation of analysis to periods 1999-2001 and 2002-2004 only. 
 
Czech Republic  849 35.8 (28.3-45.4) 46.1 (39.4-54.0) 46.9 (41.0-53.6) 11.0 0.020 
Estonia
 b
 95 - - - - - - - - 
Lithuania
 b
 186 - - - - 32.9 (22.0-49.4) - - 
Poland
 b
 225 - - - - 44.7 (33.7-59.1) - - 
Slovakia  368 51.4 (39.4-67.1) 42.0 (32.2-54.7) 46.2 (37.6-56.8) -5.2 0.269 
  Supplement 1: Age-standardised 5-year RS for oesophageal cancer in a) Northern Europe, b) 
UK and Ireland, c) Central Europe, d) Southern Europe, e) Eastern Europe and f) European 
average.  
 
a) 
 
 Note: Iceland removed as no points are available due to small number of cases 
 
b) 
 
 
c) 
 
d) 
 
Note: Malta removed as no points are available due to small number of cases 
 
 
 
 
 
 
 
e) 
 
 
f) 
 
Supplement 2: Age-standardised 5-year RS for stomach cancer in a) Northern Europe, b) 
Ireland and UK, c) Central Europe, d) Southern Europe, e) Eastern Europe and f) European 
average. 
 
a) 
 
Note: Iceland removed as no points are available due to small number of cases 
 
b) 
 
 
  
c) 
 
d) 
 
Note: Malta removed as no points are available due to small number of cases. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
e) 
 
Note: Estonia removed as no points are available due to small number of cases. 
 
f) 
 
 
Ref supplement 2f previously presented de Angelis et al., 2014[3] 
  
Supplement 3: Age-standardised 5-year RS for small intestine cancer in a)Northern Europe, 
b) Ireland and UK, c) Central Europe, d) Southern Europe, e) Eastern Europe and f) 
European average. 
 
 
a) 
 
Note: Iceland removed as no points are available due to small number of cases 
 
b) 
 
 
 
 
 
 
 
  
 
 
 
 
c) 
 
 
d) 
 
Note: Malta removed as no points are available due to small number of cases. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
e)  
 
Note: Estonia removed as no points are available due to small number of cases 
 
 
f)  
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Small Intestine cancer in Europe 
Europe
Northern EU
Ireland/UK
Central  EU
Southern  EU
Eastern  EU
Oesophagus
Age-standardised 1-year, 5-year relative survival, and 5-year relative survival conditional to 
surviving 1 year, with 95% confidence intervals in parentheses
Age-standardised 5-year relative survival (%) European age-specific and age-standardised 
observed (obs, %) and relative (rel, %) survival
Age 
group
Number
of cases
1-year 3-year 5-year
2,995 obs 51.1 26.8 20.915-44
rel 51.2 27.0 21.1
14,298 obs 46.6 19.4 14.445-54
rel 46.9 19.7 14.8
30,054 obs 45.2 18.6 13.555-64
rel 45.6 19.2 14.3
36,782 obs 39.3 16.1 11.265-74
rel 40.3 17.5 12.9
43,556 obs 27.0 8.3 4.775+
rel 29.2 10.5 7.2
127,685 obs 38.8 15.6 10.9All cases
rel 39.9 16.8 12.4
0 20 40 60 80 100
Northern Europe
Denmark
Finland
Iceland
Norway
Sweden
Ireland and UK
Ireland
UK, England
UK, Northern Ireland
UK, Scotland
UK, Wales
Central Europe
Austria
Belgium
France
Germany
Switzerland
The Netherlands
Southern Europe
Croatia
Italy
Malta
Portugal
Slovenia
Spain
Eastern Europe
Bulgaria
Czech Republic
Estonia
Latvia
Lithuania
Poland
Slovakia
Europe
1-year
Number
of cases 5-year Conditional
35.8 34.8 36.99,654 ( )-Northern Europe 10.6 9.8 11.5( )- 29.6 27.5 31.9( )-
30.0 28.4 31.83,165 ( )-Denmark 8.9 7.7 10.3( )- 29.6 25.8 33.8( )-
38.1 35.6 40.61,798 ( )-Finland 12.0 10.1 14.2( )- 31.4 26.8 36.8( )-
43.1 34.2 54.2120 ( )-Iceland - ( )- - ( )-
38.4 35.7 41.21,442 ( )-Norway 10.0 7.9 12.6( )- 25.9 20.7 32.5( )-
39.2 37.3 41.23,129 ( )-Sweden 11.7 10.2 13.3( )- 29.7 26.3 33.5( )-
39.8 39.4 40.263,179 ( )-Ireland and UK 12.5 12.1 12.8( )- 31.4 30.5 32.2( )-
41.0 39.1 43.02,673 ( )-Ireland 15.6 13.9 17.4( )- 37.9 34.2 42.0( )-
39.7 39.2 40.249,287 ( )-UK, England 12.4 12.0 12.8( )- 31.2 30.3 32.2( )-
39.0 36.3 42.01,283 ( )-UK, Northern Ireland 16.1 13.7 18.9( )- 41.3 35.8 47.6( )-
40.0 38.6 41.36,492 ( )-UK, Scotland 11.0 10.0 12.1( )- 27.5 25.1 30.2( )-
40.4 38.6 42.23,444 ( )-UK, Wales 13.1 11.7 14.8( )- 32.5 29.1 36.3( )-
45.5 44.9 46.132,860 ( )-Central Europe 15.3 14.8 15.9( )- 33.7 32.7 34.7( )-
42.8 40.8 44.92,567 ( )-Austria 16.3 14.5 18.3( )- 38.0 34.3 42.2( )-
51.8 50.2 53.53,936 ( )-Belgium 21.8 20.2 23.5( )- 42.0 39.2 45.0( )-
46.7 45.2 48.34,499 ( )-France 13.9 12.7 15.2( )- 29.7 27.3 32.2( )-
46.1 45.0 47.29,038 ( )-Germany 16.2 15.1 17.3( )- 35.1 33.0 37.3( )-
49.6 46.6 52.71,190 ( )-Switzerland 18.4 15.7 21.7( )- 37.2 32.1 43.2( )-
42.7 41.8 43.711,630 ( )-The Netherlands 13.0 12.2 13.8( )- 30.4 28.7 32.3( )-
35.5 34.6 36.412,222 ( )-Southern Europe 10.1 9.5 10.8( )- 28.5 27.0 30.2( )-
26.4 24.2 28.81,676 ( )-Croatia 10.2 8.3 12.6( )- 38.7 32.0 46.9( )-
40.3 39.0 41.75,488 ( )-Italy 11.7 10.7 12.8( )- 29.0 26.7 31.5( )-
32.3 24.2 43.286 ( )-Malta - ( )- - ( )-
33.5 31.6 35.52,530 ( )-Portugal 10.0 8.7 11.6( )- 29.9 26.1 34.1( )-
29.6 26.3 33.4712 ( )-Slovenia 8.3 6.2 11.2( )- 28.1 21.4 36.8( )-
38.2 35.9 40.71,730 ( )-Spain 9.3 7.8 11.1( )- 24.5 20.8 28.8( )-
27.0 26.0 28.09,770 ( )-Eastern Europe 7.7 7.0 8.6( )- 28.7 26.1 31.5( )-
17.8 15.4 20.41,145 ( )-Bulgaria 6.1 4.3 8.6( )- 34.4 25.0 47.3( )-
31.2 29.5 33.03,283 ( )-Czech Republic 10.6 9.2 12.2( )- 34.1 30.0 38.7( )-
28.1 23.7 33.3426 ( )-Estonia 7.0 4.4 11.2( )- 24.9 16.0 38.7( )-
28.4 24.9 32.4809 ( )-Latvia - ( )- - ( )-
24.0 21.3 27.01,121 ( )-Lithuania 5.7 3.9 8.3( )- 23.7 16.6 33.9( )-
27.2 24.7 30.11,328 ( )-Poland 6.5 4.8 8.7( )- 23.8 18.0 31.5( )-
25.7 23.3 28.41,658 ( )-Slovakia 6.9 5.2 9.2( )- 26.8 20.4 35.2( )-
39.9 39.4 40.4127,685 ( )-Europe 12.4 12.0 12.8( )- 31.0 30.1 31.9( )-
Men (71%)
2,401 obs 49.9 25.7 19.715-44
rel 50.0 25.9 19.9
11,784 obs 46.0 18.6 13.645-54
rel 46.2 18.9 14.0
24,050 obs 44.3 17.9 12.755-64
rel 44.8 18.6 13.6
27,393 obs 39.1 15.5 10.565-74
rel 40.2 16.9 12.3
24,766 obs 27.4 8.1 4.675+
rel 29.9 10.5 7.2
90,394 obs 38.5 15.0 10.3All cases
rel 39.7 16.3 11.9
Women (29%)
594 obs 56.6 32.2 27.615-44
rel 56.7 32.3 27.8
2,514 obs 50.6 24.6 20.845-54
rel 50.7 24.8 21.1
6,004 obs 50.6 23.1 18.855-64
rel 50.9 23.5 19.4
9,389 obs 40.0 19.0 14.165-74
rel 40.6 19.8 15.4
18,789 obs 26.4 8.6 5.075+
rel 28.4 10.6 7.1
37,290 obs 40.9 18.5 14.3All cases
rel 41.8 19.5 15.5
Stomach
Age-standardised 1-year, 5-year relative survival, and 5-year relative survival conditional to 
surviving 1 year, with 95% confidence intervals in parentheses
Age-standardised 5-year relative survival (%) European age-specific and age-standardised 
observed (obs, %) and relative (rel, %) survival
Age 
group
Number
of cases
1-year 3-year 5-year
10,313 obs 60.3 37.4 32.015-44
rel 60.4 37.5 32.3
22,471 obs 59.0 35.6 29.845-54
rel 59.3 36.1 30.5
47,246 obs 55.8 33.6 27.555-64
rel 56.4 34.7 29.1
84,324 obs 48.9 27.6 21.965-74
rel 50.1 29.8 25.1
115,395 obs 34.2 16.6 11.775+
rel 37.3 21.3 18.1
279,749 obs 48.3 27.4 21.9All cases
rel 49.7 29.8 25.1
0 20 40 60 80 100
Northern Europe
Denmark
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Ireland and UK
Ireland
UK, England
UK, Northern Ireland
UK, Scotland
UK, Wales
Central Europe
Austria
Belgium
France
Germany
Switzerland
The Netherlands
Southern Europe
Croatia
Italy
Malta
Portugal
Slovenia
Spain
Eastern Europe
Bulgaria
Czech Republic
Estonia
Latvia
Lithuania
Poland
Slovakia
Europe
1-year
Number
of cases 5-year Conditional
46.9 46.2 47.622,186 ( )-Northern Europe 21.9 21.2 22.6( )- 46.6 45.3 47.9( )-
39.4 37.9 41.04,188 ( )-Denmark 16.0 14.7 17.5( )- 40.6 37.6 43.9( )-
49.1 47.8 50.55,616 ( )-Finland 25.3 23.9 26.7( )- 51.4 49.0 54.0( )-
54.5 48.5 61.3275 ( )-Iceland 34.5 28.3 42.1( )- 63.3 53.9 74.2( )-
49.0 47.4 50.74,452 ( )-Norway 22.7 21.1 24.4( )- 46.3 43.4 49.3( )-
48.3 47.1 49.67,655 ( )-Sweden 21.7 20.5 22.9( )- 44.9 42.7 47.2( )-
42.1 41.7 42.570,341 ( )-Ireland and UK 17.2 16.8 17.5( )- 40.8 40.0 41.6( )-
42.3 40.6 44.03,616 ( )-Ireland 20.3 18.7 22.1( )- 48.1 44.7 51.6( )-
42.3 41.8 42.853,998 ( )-UK, England 17.0 16.6 17.4( )- 40.2 39.3 41.2( )-
41.5 39.0 44.01,854 ( )-UK, Northern Ireland 18.1 15.9 20.5( )- 43.6 38.9 48.8( )-
40.4 39.1 41.76,713 ( )-UK, Scotland 16.1 15.0 17.3( )- 39.9 37.3 42.6( )-
42.3 40.6 44.14,160 ( )-UK, Wales 17.8 16.2 19.5( )- 42.0 38.7 45.7( )-
53.3 52.9 53.768,234 ( )-Central Europe 28.1 27.6 28.5( )- 52.7 52.0 53.4( )-
54.8 53.8 55.810,569 ( )-Austria 31.0 29.9 32.2( )- 56.6 54.9 58.5( )-
56.2 54.9 57.56,650 ( )-Belgium 30.5 29.1 32.0( )- 54.4 52.2 56.7( )-
54.8 53.5 56.26,084 ( )-France 26.3 25.0 27.7( )- 47.9 45.8 50.1( )-
56.3 55.7 56.926,662 ( )-Germany 31.3 30.6 32.0( )- 55.6 54.5 56.7( )-
57.7 55.5 59.92,146 ( )-Switzerland 31.6 29.3 34.2( )- 54.9 51.3 58.7( )-
45.2 44.4 46.016,123 ( )-The Netherlands 20.4 19.7 21.3( )- 45.3 43.7 46.8( )-
52.2 51.9 52.668,213 ( )-Southern Europe 29.6 29.2 30.0( )- 56.7 56.0 57.4( )-
38.4 37.3 39.58,397 ( )-Croatia 21.3 20.2 22.5( )- 55.6 53.2 58.1( )-
56.6 56.0 57.235,428 ( )-Italy 32.4 31.7 33.0( )- 57.2 56.2 58.1( )-
41.0 35.7 47.1340 ( )-Malta 18.7 14.5 24.0( )- 45.5 36.9 56.2( )-
53.9 53.0 54.714,127 ( )-Portugal 31.8 30.9 32.7( )- 59.0 57.6 60.5( )-
46.0 44.3 47.73,617 ( )-Slovenia 26.6 24.9 28.5( )- 57.9 54.7 61.2( )-
49.4 48.1 50.76,304 ( )-Spain 25.6 24.3 26.9( )- 51.8 49.7 54.0( )-
38.4 38.0 38.950,775 ( )-Eastern Europe 18.8 18.4 19.2( )- 48.9 48.0 49.9( )-
28.8 27.9 29.611,614 ( )-Bulgaria 11.9 11.2 12.7( )- 41.4 39.1 43.9( )-
41.8 40.9 42.812,354 ( )-Czech Republic 22.0 21.1 23.0( )- 52.7 50.8 54.6( )-
44.4 42.7 46.23,242 ( )-Estonia 22.8 21.0 24.8( )- 51.4 47.9 55.2( )-
38.3 36.9 39.74,842 ( )-Latvia 20.2 18.8 21.7( )- 52.7 49.5 56.1( )-
42.5 41.3 43.76,741 ( )-Lithuania 23.1 21.9 24.4( )- 54.3 51.9 56.9( )-
38.1 36.8 39.46,112 ( )-Poland 15.6 14.4 16.8( )- 40.8 38.2 43.7( )-
43.5 42.2 44.85,870 ( )-Slovakia 20.9 19.6 22.2( )- 48.0 45.5 50.6( )-
49.7 49.4 50.0279,749 ( )-Europe 25.1 24.8 25.4( )- 50.6 50.1 51.1( )-
Men (61%)
5,712 obs 59.1 35.9 30.415-44
rel 59.2 36.1 30.8
14,758 obs 58.0 34.4 28.345-54
rel 58.3 35.0 29.2
32,479 obs 54.6 31.8 25.855-64
rel 55.3 33.0 27.6
55,667 obs 47.9 25.7 19.965-74
rel 49.4 28.2 23.4
61,560 obs 33.7 15.4 10.575+
rel 36.9 20.4 17.0
170,176 obs 47.3 25.9 20.3All cases
rel 48.9 28.4 23.7
Women (39%)
4,601 obs 61.9 39.3 34.115-44
rel 62.0 39.4 34.2
7,713 obs 60.9 37.9 32.645-54
rel 61.1 38.2 33.1
14,767 obs 58.6 37.8 31.555-64
rel 58.9 38.5 32.5
28,657 obs 50.8 31.5 26.265-74
rel 51.5 33.0 28.5
53,835 obs 34.9 18.0 13.175+
rel 37.7 22.4 19.2
109,573 obs 50.0 30.3 24.9All cases
rel 51.1 32.3 27.7
Small intestine
Age-standardised 1-year, 5-year relative survival, and 5-year relative survival conditional to 
surviving 1 year, with 95% confidence intervals in parentheses
Age-standardised 5-year relative survival (%) European age-specific and age-standardised 
observed (obs, %) and relative (rel, %) survival
Age 
group
Number
of cases
1-year 3-year 5-year
1,490 obs 86.2 72.5 67.315-44
rel 86.3 72.8 67.9
2,756 obs 82.5 67.9 59.745-54
rel 82.9 68.9 61.2
5,141 obs 74.6 58.8 51.055-64
rel 75.3 60.6 53.8
6,577 obs 66.5 49.2 41.065-74
rel 68.0 52.8 46.6
7,314 obs 47.7 28.9 23.075+
rel 51.4 36.2 34.2
23,278 obs 66.2 49.4 42.2All cases
rel 67.9 53.1 47.9
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Poland
Slovakia
Europe
1-year
Number
of cases 5-year Conditional
73.5 72.1 75.03,828 ( )-Northern Europe 52.5 50.5 54.6( )- 71.5 69.1 73.9( )-
59.8 56.0 63.7600 ( )-Denmark 36.8 32.4 41.9( )- 61.6 55.1 69.0( )-
76.0 72.7 79.5644 ( )-Finland 56.0 51.2 61.2( )- 73.7 68.2 79.6( )-
77.5 64.7 92.944 ( )-Iceland 45.3 31.2 65.7( )- 58.4 42.2 80.8( )-
75.1 72.1 78.1821 ( )-Norway 55.0 50.8 59.4( )- 73.2 68.4 78.3( )-
76.2 74.2 78.31,719 ( )-Sweden 55.7 52.7 58.9( )- 73.0 69.5 76.7( )-
58.8 57.6 59.96,948 ( )-Ireland and UK 36.9 35.5 38.3( )- 62.8 60.7 64.9( )-
66.1 61.5 71.0383 ( )-Ireland 43.0 37.2 49.8( )- 65.1 57.3 73.9( )-
57.5 56.2 58.95,361 ( )-UK, England 36.4 34.9 38.1( )- 63.3 61.0 65.7( )-
57.1 50.3 64.7187 ( )-UK, Northern Ireland 34.6 26.9 44.5( )- 60.6 48.8 75.3( )-
63.8 60.1 67.8612 ( )-UK, Scotland 38.4 33.6 43.8( )- 60.1 53.4 67.6( )-
61.7 57.1 66.6405 ( )-UK, Wales 37.3 31.7 43.8( )- 60.4 52.4 69.6( )-
74.1 73.1 75.26,754 ( )-Central Europe 53.9 52.4 55.4( )- 72.7 70.9 74.5( )-
74.7 71.8 77.7889 ( )-Austria 54.6 50.6 59.0( )- 73.1 68.4 78.1( )-
75.1 72.2 78.1841 ( )-Belgium 55.8 51.7 60.3( )- 74.3 69.6 79.4( )-
74.4 71.3 77.5802 ( )-France 50.8 47.0 55.0( )- 68.4 63.9 73.1( )-
77.2 75.4 79.12,151 ( )-Germany 57.7 54.9 60.7( )- 74.7 71.5 78.1( )-
78.9 74.7 83.4348 ( )-Switzerland 58.6 52.4 65.4( )- 74.2 67.4 81.6( )-
68.5 66.3 70.81,723 ( )-The Netherlands 48.9 46.0 52.1( )- 71.4 67.7 75.4( )-
66.2 64.7 67.73,677 ( )-Southern Europe 46.8 44.9 48.7( )- 70.6 68.3 73.1( )-
53.3 47.9 59.4286 ( )-Croatia 42.3 35.4 50.6( )- 79.4 68.8 91.5( )-
69.7 67.8 71.62,206 ( )-Italy 49.0 46.7 51.6( )- 70.4 67.5 73.4( )-
68.7 51.2 92.230 ( )-Malta 23.5 13.4 40.9( )- 34.1 21.3 54.7( )-
62.3 58.6 66.2626 ( )-Portugal 42.4 38.0 47.3( )- 68.1 62.1 74.6( )-
64.5 57.6 72.2158 ( )-Slovenia 44.4 36.1 54.8( )- 68.9 57.8 82.2( )-
61.5 56.8 66.6371 ( )-Spain 45.4 40.1 51.3( )- 73.7 67.2 81.0( )-
61.4 59.2 63.62,071 ( )-Eastern Europe 43.0 40.1 46.0( )- 70.0 66.1 74.2( )-
55.5 49.1 62.8262 ( )-Bulgaria 36.6 28.5 46.8( )- 65.9 53.1 81.7( )-
64.6 61.5 67.9890 ( )-Czech Republic 47.4 43.1 52.2( )- 73.4 67.6 79.7( )-
64.4 54.6 76.087 ( )-Estonia 42.2 29.7 60.1( )- 65.5 48.0 89.6( )-
53.7 44.3 65.1101 ( )-Latvia 39.6 28.7 54.6( )- 73.7 56.9 95.3( )-
56.8 49.4 65.2161 ( )-Lithuania 32.5 24.8 42.7( )- 57.3 45.3 72.3( )-
58.3 52.0 65.3229 ( )-Poland 40.0 32.7 49.0( )- 68.7 58.0 81.3( )-
63.2 58.1 68.9341 ( )-Slovakia 46.3 39.8 53.9( )- 73.2 64.5 83.0( )-
67.9 67.0 68.923,278 ( )-Europe 47.9 46.7 49.1( )- 70.5 69.0 72.0( )-
Men (54%)
816 obs 84.4 68.1 63.915-44
rel 84.5 68.5 64.6
1,663 obs 81.3 65.8 58.345-54
rel 81.7 66.9 60.1
2,977 obs 72.5 55.9 46.855-64
rel 73.3 58.1 50.0
3,729 obs 65.4 47.3 39.165-74
rel 67.3 51.7 46.0
3,416 obs 47.7 27.3 22.675+
rel 52.0 35.5 35.9
12,601 obs 65.1 47.1 40.1All cases
rel 67.2 51.5 47.0
Women (46%)
674 obs 89.1 78.4 71.715-44
rel 89.2 78.6 72.1
1,093 obs 84.5 71.3 62.445-54
rel 84.7 71.9 63.3
2,164 obs 77.7 63.6 57.455-64
rel 78.1 64.7 59.3
2,848 obs 67.8 51.7 43.765-74
rel 68.8 54.1 47.6
3,897 obs 47.8 30.1 24.375+
rel 51.0 36.5 33.9
10,676 obs 67.8 52.4 45.4All cases
rel 69.1 55.3 49.9
